|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analysis among patients with tumor size ≤ 5.0 cm (n=109), patients at Barcelona Clinic Liver Cancer stage 0 or A (n=92), and patients with α-fetoprotein ≤ 20 ng/mL (n=61), the ATAD2-positive groups unfavorably influenced RFS (p=0.008, p=0.009, and p=0.013, respectively).
|
25687855 |
2015 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed that younger age, normal alpha fetoprotein, single site of extra-hepatic disease, local treatment to the primary tumor and surgery to the metastatic disease were associated with better overall survival and liver cancer-specific survival.
|
28276812 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using multivariate Cox regression analyses, the patient-related eGFRcre/eGFRcys ratio (hazard ratio [HR], 4.178; P = 0.007), as well as the tumor-related factors α-fetoprotein (HR, 1.000; P < 0.001) and Barcelona Clinic Liver Cancer stage (HR, 2.589; P < 0.001), were independent predictors of survival.
|
30005446 |
2019 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of clinicopathologic analysis showed that A allele at the rs737241 locus could increase the expression level of AFP (P = .007), the rs1046282 mutation C allele could increase the AFP expression level (P = .011), rs4024 locus mutation A allele could reduce the risk of vascular invasion (P = .013), rs3212948 locus mutation T allele could reduce the differentiation of liver cancer (P = .022), rs1046282 locus C allele could reduce the DNA load of hepatitis B virus (P = .035), and rs735482 A allele could increase the tumor size in HCC (P = .037).The SNPs in rs737241 for AFP gene may correlate with the occurrence of HCC.
|
30946366 |
2019 |
|
Adult Liver Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the liver cancer-specific oncolytic potential of E1B 55kDa-deleted recombinant adenovirus (YKL-1001), which retained other E1 genes driven by the AFP promoter.
|
11911966 |
2002 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma Hsp90α maintains also broad-spectrum for cancer subtypes, especially with 91.78% sensitivity and 91.96% specificity in patients with AFP-limited liver cancer.
|
31343810 |
2019 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the idea that ZHX2 contributes to AFP repression in the liver after birth and may also be involved in AFP reactivation in liver cancer.
|
18194454 |
2008 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentration of alpha-fetoprotein (AFP) rises greatly in patients with liver cancer and it is a challenge to construct a sensitive AFP detection method with wide range.
|
31761168 |
2020 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to the small risk of liver cancer development, screening for liver cancer (especially HCC) is still recommended in HT1 patients using regular measures of α-fetoprotein and imaging.
|
28755188 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate and multivariate analyses revealed the SHI was an independent predictor for overall survival and relapse-free survival, and prognostic for patients with negative α-fetoprotein and Barcelona Clinic Liver Cancer stage 0+A.
|
28769812 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFP is an important target in the treatment of liver cancer.
|
28554567 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum AFP elevation by the infection of HBV and HCV is one of mechanisms which lead to hepatocarcinogenesis, and the antivirus intervening treatment of hepatitis is significant for the prognosis of liver cancer.
|
17465484 |
2007 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy.
|
29805966 |
2018 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous studies indicated that targeted expression of therapeutic BikDD driven by a liver cancer-specific α-fetoprotein promoter/enhancer (eAFP) in the VISA backbone (eAFP-VISA-BikDD) significantly and specifically kills HCC cells in multiple orthotopic animal models.
|
26247632 |
2015 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One-shot transfusion of hepatoma serum to naïve rats induced liver cancer development with gradual elevation of alpha-fetoprotein (AFP), but exosome-free hepatoma serum failed to induce AFP elevation.
|
31162867 |
2019 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The detection rate of AFP for liver cancer was 86.8%, and the exclusive diagnostic rate of AFP for hepatic FNH was 96.9%.
|
31646787 |
2020 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experiments were conducted in vivo using systemic administration of Adv-AFP-E1AdB and we observed tumor size reduction in nude mice having liver cancer.
|
11401492 |
2001 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%).
|
28011514 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conductometric immunoassay of alpha-fetoprotein in sera of liver cancer patients using bienzyme-functionalized nanometer-sized silica beads.
|
30398232 |
2018 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Fetoprotein (AFP), which is a serological marker of liver cancer, was used as a model analyte to test STA-AQ in an immunoassay.
|
21389603 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a proof of concept, α-fetoprotein (AFP) was detected as a target, which is a biomarker of liver cancer.
|
28155925 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel label-free immunosensor based on hyperbranched polyester nanoparticles with nitrite groups (HBPE-NO<sub>2</sub>), which were synthesized through a simple one-step chemical reaction, was first developed for specific detection of α-fetoprotein (AFP), the tumor marker for liver cancer.
|
28167413 |
2017 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a 32-gene diagnostic model that accurately distinguished early HCC (stage 0/A) based on the Barcelona Clinic Liver Cancer staging system from non-HCC (validation set: area under curve (AUC)=88.4%; (95% CI 85.8% to 91.1%)), showing superior performance over α-fetoprotein (AFP).
|
31358576 |
2019 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the transcription factors that regulate AFP in the fetal liver, as well as Zhx2 and Zbtb20, and raise the possibility that the loss of these postnatal repressors may be involved in AFP reactivation in liver cancer.
|
21216289 |
2011 |
|
Adult Liver Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, to overcome water absorption and enhance the THz biosensing sensitivity, two kinds of THz metamaterials biosensor integrated with microfluidics were fabricated and used to detect the Alpha fetoprotein (AFP) and Glutamine transferase isozymes II (GGT-II) of liver cancer biomarker in early stage.
|
29180650 |
2017 |